Logo
x

Search

Subscribe Now

All Posts by Date

Novartis' Xolair (omalizumab) Receives EU's Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)

Novartis' Xolair (omalizumab) Receives EU's Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)

  • December 14, 2018
Vertex's Orkambi (lumacaftor/ivacaftor) Receives Health Canada Approval for Cystic Fibrosis (CF) Aged 2 to 5 yrs.

Vertex's Orkambi (lumacaftor/ivacaftor) Receives Health Canada Approval for Cystic Fibrosis (CF) Aged 2 to 5 yrs.

  • December 14, 2018
Axovant Sciences Licenses Two Gene Therapy Programs from University of Massachusetts for Rare and Fatal Neurodegenerative Genetic Disorders

Axovant Sciences Licenses Two Gene Therapy Programs from University of Massachusetts for Rare and Fatal Neurodegenerative Genetic...

  • December 14, 2018
Eli Lilly's Olumiant (baricitinib) Receives FDA's Fast Track Designation for Systemic Lupus Erythematosus (SLE)

Eli Lilly's Olumiant (baricitinib) Receives FDA's Fast Track Designation for Systemic Lupus Erythematosus (SLE)

  • December 14, 2018
Celltrion and Teva's Herzuma (trastuzumab-pkrb- Herceptin biosimilar) Receives FDA's Approval for HER2-Overexpressing Breast Cancer

Celltrion and Teva's Herzuma (trastuzumab-pkrb- Herceptin biosimilar) Receives FDA's Approval for HER2-Overexpressing Breast Cance...

  • December 14, 2018
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.